Homeoproteins as novel therapies for neurodegenerative diseasesbroad
HOMEOBRAIN · Horizon Europe grant · 2022-11-01–2024-10-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases. At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs). Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration. When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases. In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1, to treat patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD).
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| BRAINEVER | FR | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.